Physician profile
Michelle Millman
NPI 1801263512
$7,065.11
in general payments reported to CMS, 2019-2025
33 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $790 · 2022: $1,511 · 2023: $1,416 · 2024: $1,652 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,764.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,698.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $924.78 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $738.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $521.80 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.19 | 2021-2025 | Jardiance, Stiolto Respimat |
| Glaxosmithkline, LLC. | $394.72 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $382.21 | 2021-2025 | |
| Abbott Laboratories | $285.88 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $254.03 | 2021-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $215.09 | 2022-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.46 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $145.58 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $121.56 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $107.50 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $71.78 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $61.56 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $49.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $48.77 | 2021-2022 | |
| Dexcom, INC. | $48.60 | 2024-2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $47.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.64 | 2022-2023 | Trintellix |
| Viatris Specialty LLC | $36.95 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $36.12 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $34.83 | 2021 | |
| Alkermes, INC. | $32.40 | 2023-2025 | Aristada, Lybalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.83 | 2021-2024 | Xifaxan |
| Abiomed | $23.49 | 2024 | |
| Pulmonx Corporation | $19.11 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $18.01 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.52 | 2025 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $14.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.01 | 2021 | |
| Merck Sharp & Dohme LLC | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Millman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.